Zeria Pharmaceutical

CompanyJapan

Zeria Pharmaceutical develops one asset, approved (patiromer in hyperkalemia). Mostly other; based in Japan.

1
Asset
Furthest stage
Approved
2
Trials
4
Signals

Pipeline

1
  • patiromer

    Binds potassium in the gastrointestinal tract, increasing fecal potassium excretion and lowering blood potassium.

    Approved, Other, hyperkalemia, chronic kidney disease (Phase 2)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials4
  • Signals5
  • Similar companies6

Intelligence